BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Madelain V, Guedj J, Mentré F, Nguyen TH, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H. Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. Antimicrob Agents Chemother 2017;61:e01305-16. [PMID: 27736754 DOI: 10.1128/AAC.01305-16] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Brisse ME, Ly H. Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors. Front Immunol 2019;10:372. [PMID: 30918506 DOI: 10.3389/fimmu.2019.00372] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
2 Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens RW, Razonable RR. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof). Mayo Clin Proc. 2020;95:1454-1466. [PMID: 32561148 DOI: 10.1016/j.mayocp.2020.04.027] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 19.5] [Reference Citation Analysis]
3 Bricker TL, Shafiuddin M, Gounder AP, Janowski AB, Zhao G, Williams GD, Jagger BW, Diamond MS, Bailey T, Kwon JH, Wang D, Boon ACM. Therapeutic efficacy of favipiravir against Bourbon virus in mice. PLoS Pathog 2019;15:e1007790. [PMID: 31194854 DOI: 10.1371/journal.ppat.1007790] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
4 Anantpadma M, Lane T, Zorn KM, Lingerfelt MA, Clark AM, Freundlich JS, Davey RA, Madrid PB, Ekins S. Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads. ACS Omega 2019;4:2353-61. [PMID: 30729228 DOI: 10.1021/acsomega.8b02948] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
5 Andrade BS, Rangel FS, Santos NO, Freitas ADS, Soares WRA, Siqueira S, Barh D, Góes-Neto A, Birbrair A, Azevedo VAC. Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. Front Pharmacol 2020;11:590598. [PMID: 33390967 DOI: 10.3389/fphar.2020.590598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J. Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nat Commun 2018;9:4013. [PMID: 30275474 DOI: 10.1038/s41467-018-06215-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
7 Franco EJ, Rodriquez JL, Pomeroy JJ, Hanrahan KC, Brown AN. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines. Antivir Chem Chemother 2018;26:2040206618807580. [PMID: 30354193 DOI: 10.1177/2040206618807580] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
8 Kumari P, Rawat K, Saha L. Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. Curr Pharmacol Rep 2020;:1-13. [PMID: 32837854 DOI: 10.1007/s40495-020-00226-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Mikhail IE, Elmansi H, Belal F, Ehab Ibrahim A. Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens. Microchem J 2021;165:106189. [PMID: 33776146 DOI: 10.1016/j.microc.2021.106189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med 2018;15:e1002535. [PMID: 29584730 DOI: 10.1371/journal.pmed.1002535] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 17.3] [Reference Citation Analysis]
11 Lingas G, Rosenke K, Safronetz D, Guedj J. Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. PLoS Comput Biol 2021;17:e1008535. [PMID: 33411731 DOI: 10.1371/journal.pcbi.1008535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, Hens B, Vergote V, Heylen E, Barthelemy K, Maas E, De Keyzer C, Bervoets L, Rymenants J, Van Buyten T, Zhang X, Abdelnabi R, Pang J, Williams R, Thibaut HJ, Dallmeier K, Boudewijns R, Wouters J, Augustijns P, Verougstraete N, Cawthorne C, Breuer J, Solas C, Weynand B, Annaert P, Spriet I, Vande Velde G, Neyts J, Rocha-Pereira J, Delang L. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci USA. 2020;117:26955-26965. [PMID: 33037151 DOI: 10.1073/pnas.2014441117] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 38.5] [Reference Citation Analysis]
13 Driouich JS, Cochin M, Lingas G, Moureau G, Touret F, Petit PR, Piorkowski G, Barthélémy K, Laprie C, Coutard B, Guedj J, de Lamballerie X, Solas C, Nougairède A. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat Commun 2021;12:1735. [PMID: 33741945 DOI: 10.1038/s41467-021-21992-w] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 24.0] [Reference Citation Analysis]
14 Pires de Mello CP, Tao X, Kim TH, Bulitta JB, Rodriquez JL, Pomeroy JJ, Brown AN. Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens. Antimicrob Agents Chemother 2018;62:e01983-17. [PMID: 29109164 DOI: 10.1128/AAC.01983-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
15 Best K, Guedj J, Madelain V, de Lamballerie X, Lim SY, Osuna CE, Whitney JB, Perelson AS. Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. Proc Natl Acad Sci U S A 2017;114:8847-52. [PMID: 28765371 DOI: 10.1073/pnas.1704011114] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 12.6] [Reference Citation Analysis]
16 Skarmoutsos I, Maurin G, Guardia E, Samios J. Hydration Structure and Dynamics of the Favipiravir Antiviral Drug: A Molecular Modelling Approach. BCSJ 2020;93:1378-85. [DOI: 10.1246/bcsj.20200163] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Madelain V, Mentré F, Baize S, Anglaret X, Laouénan C, Oestereich L, Nguyen THT, Malvy D, Piorkowski G, Graw F, Günther S, Raoul H, de Lamballerie X, Guedj J. Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT Pharmacometrics Syst Pharmacol 2020;9:258-71. [PMID: 32198838 DOI: 10.1002/psp4.12510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Lane TR, Massey C, Comer JE, Freiberg AN, Zhou H, Dyall J, Holbrook MR, Anantpadma M, Davey RA, Madrid PB, Ekins S. Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig. Antiviral Res 2020;181:104863. [PMID: 32682926 DOI: 10.1016/j.antiviral.2020.104863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Moriiwa Y, Morikawa G, Okazawa K, Yanagida A. Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19. Anal Sci 2021;37:1301-4. [PMID: 33612558 DOI: 10.2116/analsci.21N004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]